Scholarlink

<p>The optimal myeloablative conditioning regimen for adolescents and young adults with acute myeloid leukaemia (AML) is currently unknown. In this retrospective analysis conducted on AML patients aged 18-40 years, in complete remission (CR), who received an allogeneic hematopoietic cell transplantation (HCT) we compared outcomes of different conditioning regimens. A total of 4323 patients, with median age of 30.9 years, transplanted from 2010 to 2022, received one of four regimens: high-dose total body irradiation (TBI)-based (<i>n</i> = 1031), thiotepa-busulfan (Bu)-fludarabine (Flu) (TBF) <i>n</i> = 219, Bu-Flu (<i>n</i> = 1100), and Bu-cyclophosphamide (Cy) (<i>n</i> = 1973). Prolonged OS and PFS for Bu-Flu (hazard ratio [HR] 0.73, 95% CI 0.57–0.92, <i>p</i> = 0.008; HR 0.78, 95% CI 0.64–0.94, <i>p</i> = 0.01), and TBF (HR 0.59, 95% CI 0.38-0.92, <i>p</i> = 0.02; HR 0.67, 95% CI 0.47–0.94, <i>p</i> = 0.02), respectively, as well as less RI for both Bu-Flu (HR 0.77, 95% CI 0.63–0.95, <i>p</i> = 0.01), and TBF (HR 0.68, 95% CI 0.47–0.99, <i>p</i> = 0.046). In conclusion, young adult AML patients seem to benefit from high dose TBI-free regimens, in terms of survival and toxicity, with four major myeloablative regimens. TBF and Bu-Flu were associated with better clinical outcomes, partly reflecting the general improvement in supportive therapies and patient selection introduced in recent years. Prospective clinical trials are warranted.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of conditioning regimen on outcomes of young AML patients ( < 40 years) undergoing HCT in complete remission, with transplant conditioning intensity score of 3.5-4.0. A study from the acute leukemia working party of the European Society for Blood and Marrow Transplantation

  • 期刊论文

  • 发表日期：

    2026年7月17日

查看全文
  • Enrico Maffini,
  • Maud Ngoya,
  • Mohamed Houhou,
  • Malek Benakli,
  • Babak Bahar,
  • Mahmoud Aljurf,
  • Khalid Halahleh,
  • Regis Peffault de Latour,
  • Igor-Wolfgang Blau,
  • Andrew Clark,
  • Catherine Flynn,
  • Peter Pal Remenyi,
  • Maria Losa Maroto,
  • Ibrahim Yakoub-Agha,
  • Henrik Sengeloev,
  • Cristina Castilla-Llorente,
  • Emma Nicholson,
  • Urpu Salmenniemi,
  • Radovan Vrhovac,
  • Jakob Passweg,
  • Matthias Eder,
  • Etienne Daguindau,
  • Alexandros Spyridonidis,
  • Arnon Nagler,
  • Fabio Ciceri,
  • Mohamad Mohty

摘要

The optimal myeloablative conditioning regimen for adolescents and young adults with acute myeloid leukaemia (AML) is currently unknown. In this retrospective analysis conducted on AML patients aged 18-40 years, in complete remission (CR), who received an allogeneic hematopoietic cell transplantation (HCT) we compared outcomes of different conditioning regimens. A total of 4323 patients, with median age of 30.9 years, transplanted from 2010 to 2022, received one of four regimens: high-dose total body irradiation (TBI)-based (n = 1031), thiotepa-busulfan (Bu)-fludarabine (Flu) (TBF) n = 219, Bu-Flu (n = 1100), and Bu-cyclophosphamide (Cy) (n = 1973). Prolonged OS and PFS for Bu-Flu (hazard ratio [HR] 0.73, 95% CI 0.57–0.92, p = 0.008; HR 0.78, 95% CI 0.64–0.94, p = 0.01), and TBF (HR 0.59, 95% CI 0.38-0.92, p = 0.02; HR 0.67, 95% CI 0.47–0.94, p = 0.02), respectively, as well as less RI for both Bu-Flu (HR 0.77, 95% CI 0.63–0.95, p = 0.01), and TBF (HR 0.68, 95% CI 0.47–0.99, p = 0.046). In conclusion, young adult AML patients seem to benefit from high dose TBI-free regimens, in terms of survival and toxicity, with four major myeloablative regimens. TBF and Bu-Flu were associated with better clinical outcomes, partly reflecting the general improvement in supportive therapies and patient selection introduced in recent years. Prospective clinical trials are warranted.